logo
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Yahoo27-05-2025

NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ('Traws Pharma', 'Traws' or 'the Company'), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Agency). The FDA provided feedback on development paths for potential approval of tivoxavir marboxil (TXM) for bird flu and seasonal flu, including on the use of the Animal Rule. The Animal Rule is intended to provide a path to approval in situations when human clinical studies would be unethical or impractical.
'The FDA has provided detailed feedback on the development paths for approval, including a combined clinical study enrolling seasonal flu and bird flu-infected subjects, as such infections occur. We are requesting a Type D meeting with the FDA to specify next steps and look forward to working closely with the Agency to develop TXM for bird flu and seasonal flu,' said C. David Pauza, PhD, Chief Science Officer for Traws Pharma.
'The consistent finding of therapeutic effects of TXM in three animal models of bird flu increases our confidence that this compound should be rapidly progressed for stockpiling and pandemic readiness by government agencies,' said Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC). 'To that end, we have initiated a dialog with the Biomedical Advanced Research and Development Authority (BARDA), the responsible agency for stockpiling for pandemic preparedness in the United States, and we plan to engage with respective international regulatory agencies for the same purpose. With the known history that previous H5N1 virus outbreaks in human populations are associated with death rates of up to 50%1, we believe that these actions should be pursued with great urgency.'
'This initial interaction with the FDA has helped guide the development of TXM as a broad therapeutic against pandemic and seasonal influenza,' commented Iain Dukes, MA DPhil, Interim CEO of Traws Pharma. 'We are committed to progressing the process for stockpiling TXM to prevent any pandemic outbreaks associated with bird flu.'
About Tivoxavir Marboxil
Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza. It has potent in vitro activity against a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent, positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1 bird flu. Seasonal influenza represents an estimated multi-billion dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders2,3, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. We believe that these data support further development of tivoxavir marboxil as a treatment for bird flu and seasonal flu.
Source information:
Per link
Per link
TRAW data on file
About Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, benefits and the regulatory plans for tivoxavir marboxil. The Company has attempted to identify forward-looking statements by terminology including 'believes', 'estimates', 'anticipates', 'expects', 'plans', 'intends', 'may', 'could', 'might', 'will', 'should', 'preliminary', 'encouraging', 'approximately' or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws' clinical trials, our ability to take advantage of expedited regulatory pathways for tivoxavir marboxil, our ability to obtain regulatory approval of tivoxavir marboxil, the expectations of our interactions with regulatory authorities, including both the FDA and BARDA and international regulatory agencies, market conditions, regulatory requirements, changes in government regulation, the extent of the spread and threat of the bird flu, and those discussed under the heading 'Risk Factors' in Traws' filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Traws Pharma Contact:Nora BrennanTraws Pharma, Inc.nbrennan@trawspharma.comwww.trawspharma.com
Investor Contact:Bruce Mackle LifeSci Advisors, LLC646-889-1200bmackle@lifesciadvisors.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

Yahoo

time27 minutes ago

  • Yahoo

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio

Colliers publishes 2024 Global Sustainability Report
Colliers publishes 2024 Global Sustainability Report

Hamilton Spectator

time44 minutes ago

  • Hamilton Spectator

Colliers publishes 2024 Global Sustainability Report

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ and TSX: CIGI) released its 2024 Global Sustainability Report , highlighting the firm's achievements and progress against targets established in 2021. The report also offers a first look at Colliers' refreshed sustainability strategy, Built to Last , which is based on an updated materiality assessment conducted in the first quarter of 2025. The strategy is designed to align Colliers' priorities with today's most pressing environmental, social, and governance challenges and opportunities, anchored around three core pillars: 'As a global provider of real estate, engineering and investment management services, we are in a unique position to help owner, investor and occupier clients realize their sustainability aspirations while driving the same positive impact for our own operations,' said Jay Hennick, Global Chairman & CEO of Colliers. 'I'm proud of our 2024 performance and remaining agile in our approach to what's next. I look forward to continuing our journey toward a more sustainable future though Built to Last.' Highlights from the 2024 report include: To support the next phase of our sustainability leadership, Tonya Lagrasta has been appointed Global Head of Sustainability at Colliers. A long-time sustainability leader and trusted advisor within our business, Tonya brings more than 20 years of experience across sectors including commercial real estate, retail, consumer goods, financial services, pharmaceuticals, and the public sector. In this role she will spearhead the implementation of Built to Last and drive integration of sustainability across Colliers. 'Sustainability is a reflection of our values in action, and a pathway to long-term resilience,' said Lagrasta. 'Built to Last reflects where we are today – and more importantly, where we're going. I'm energized by our people's passion and proud to help lead this next chapter of impact.' The full 2024 Global Sustainability Report is available at . About Colliers Colliers (NASDAQ, TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading platforms – Real Estate Services, Engineering, and Investment Management – we have a proven business model, an enterprising culture, and a unique partnership philosophy that drives growth and value creation. For 30 years, Colliers has consistently delivered approximately 20% compound annual returns for shareholders, fueled by visionary leadership, significant inside ownership and substantial recurring earnings. With nearly $5.0 billion in annual revenues, a team of 23,000 professionals, and more than $100 billion in assets under management, Colliers remains committed to accelerating the success of our clients, investors, and people worldwide. Learn more at , X @Colliers or LinkedIn . Media Contact Andrea Cheung Senior Manager, Global Integrated Communications +1 416 324 6402

Colliers publishes 2024 Global Sustainability Report
Colliers publishes 2024 Global Sustainability Report

Yahoo

timean hour ago

  • Yahoo

Colliers publishes 2024 Global Sustainability Report

Launches refreshed sustainability strategy Built to Last TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ and TSX: CIGI) released its 2024 Global Sustainability Report, highlighting the firm's achievements and progress against targets established in 2021. The report also offers a first look at Colliers' refreshed sustainability strategy, Built to Last, which is based on an updated materiality assessment conducted in the first quarter of 2025. The strategy is designed to align Colliers' priorities with today's most pressing environmental, social, and governance challenges and opportunities, anchored around three core pillars: Environmental sustainability: Supporting decarbonization and climate resilience Workplace experience: Creating inclusive, healthy, high-performing spaces Ethical governance & practices: Embedding trust, transparency, and responsible innovation 'As a global provider of real estate, engineering and investment management services, we are in a unique position to help owner, investor and occupier clients realize their sustainability aspirations while driving the same positive impact for our own operations,' said Jay Hennick, Global Chairman & CEO of Colliers. 'I'm proud of our 2024 performance and remaining agile in our approach to what's next. I look forward to continuing our journey toward a more sustainable future though Built to Last.' Highlights from the 2024 report include: Achieved a 27.6% reduction in Scope 1 and 2 emissions per square foot from our 2021 baseline. Earned WELL Health-Safety Ratings in 87.4% of Colliers offices ≥ 2,500 sq. ft., up from 35% in 2022. Expanded our electric vehicle fleet to 170+, representing a 5x increase in just two years. Reached 88% participation in our global employee engagement survey, with scores exceeding external benchmarks. 68% of our Colliers Gives volunteering goal achieved. To support the next phase of our sustainability leadership, Tonya Lagrasta has been appointed Global Head of Sustainability at Colliers. A long-time sustainability leader and trusted advisor within our business, Tonya brings more than 20 years of experience across sectors including commercial real estate, retail, consumer goods, financial services, pharmaceuticals, and the public sector. In this role she will spearhead the implementation of Built to Last and drive integration of sustainability across Colliers. 'Sustainability is a reflection of our values in action, and a pathway to long-term resilience,' said Lagrasta. 'Built to Last reflects where we are today – and more importantly, where we're going. I'm energized by our people's passion and proud to help lead this next chapter of impact.' The full 2024 Global Sustainability Report is available at About Colliers Colliers (NASDAQ, TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading platforms – Real Estate Services, Engineering, and Investment Management – we have a proven business model, an enterprising culture, and a unique partnership philosophy that drives growth and value creation. For 30 years, Colliers has consistently delivered approximately 20% compound annual returns for shareholders, fueled by visionary leadership, significant inside ownership and substantial recurring earnings. With nearly $5.0 billion in annual revenues, a team of 23,000 professionals, and more than $100 billion in assets under management, Colliers remains committed to accelerating the success of our clients, investors, and people worldwide. Learn more at X @Colliers or LinkedIn. Media Contact Andrea CheungSenior Manager, Global Integrated Communications+1 416 324 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store